Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 6 - Studien 51 bis 60 von insgesamt 78
- Rekrutierung läuftEvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
- Rekrutierung läuftOhrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie
- Rekrutierung läuftA Multi-National Prospective non interventional study of standard of care in participants with MM who are refractory to at least one Proteasome inhibitor, one immunmodulatory Drug and one anti-CD38 antibody
- Rekrutierung läuftPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Rekrutierung läuftA Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refracotroy Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lanalidomide. MonumenTAL-664407564MMY3009
2022-502446-27-00 ( Registry Identifier: EUCT number ) - Rekrutierung läuftMYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)
- Rekrutierung läuftAn Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovirin Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas(NAVAL-1)Molekulare Marker
- Rekrutierung läuftNicht – interventionelle Unbedenklichkeitsstudie zur Verträglichkeit und Sicherheit von Octagam 5 % und Octagam 10 %; Therapie im Rahmen der Zulassung